Re: Riordan Clinic Research Institute -Test for Energy Metabolism in CFS

[Guest guest]

Dear Al

Thanks for the heads-up on this. It's an area that has been under the

spotlight several times. Unfortunately, as is usual, people who resort to

patenting their findings often do so to obscure the factual content of their

discoveries rather than to illuminate them. In this case, a (fairly

superficial) search of USPTO records reveals nothing. How have they

concealed it? It's not listed by any of the identifiers used in the

article quoted below. Still, it's better to live in hope than die in

despair.

Regards

R

[CO-CURE] RES: Riordan Clinic Research Institute Has Developed

and Patented a Process for the Assessment of the Energy Metabolism in

Patients with Chronic Fatigue Syndrome.

Date: Thu, 12 Apr 2012 07:49:48 -0500

From: kelly <kellylatta66@...>

Reply-kelly <kellylatta66@...>

CO-CURE@...

Note: This is a public relations press release that was printed

verbatim on the site. Press releases are specifically designed to

follow a news format, in general, however rarely cite more than one

source and do not present caveats such as adverse effects, cost etc.

The study is not available through PubMed. Whether or not it would

specifically assess post exertional malaise (PEM) which appears to

differentiate ME and CFS patients from nearly all other medical

patients with " fatigue " is unknown.

Bio-medicine

4/11/2012

Riordan Clinic Research Institute Has Developed and Patented a Process

for the Assessment of the Energy Metabolism in Patients with Chronic

Fatigue Syndrome.

WICHITA, Kan., April 11, 2012 /PRNewswire-USNewswire/ --Riordan Clinic

scientists Dr. Nina Mikirova, Dr. ph Casciari, and Dr.

Hunninghake have patented a new technology that may help doctors

determine the severity of fatigue in their patients.

The research, recently published in the January/February issue of the

journal, Alternative Therapies, is entitled " The Assessment of the

Energy Metabolism in Patients with Chronic Fatigue Syndrome by Serum

Fluorescence Emission. "

Chronic fatigue syndrome (CFS) is characterized by long-lasting

disabling fatigue. It includes non-specific symptoms such as weakness,

malaise, subjective fever, sore throat, lymph node pain, and decreased

memory. There are no conclusive diagnostic tests for CFS. Since the

underlying mechanism for CFS is not known, finding reliable biomarkers

for diagnosing are important.

The purpose of this study was to examine the use of serum nicotinamide

adenine dinucleotide (NAD(P)H) levels as a metabolic marker of fatigue

state and alterations in metabolism and homeostasis in CFS patients.

The Riordan Clinic scientists have developed a method of determining

NAD(P)H levels based on fluorescence emission of serum at 450 nm.

Serum NAD(P)H concentrations were compared for subjects with CFS and

healthy controls. NAD(P)H concentrations in the serum of CFS subjects

averaged 8.0 +/- 1.4 (SD) uM while those in healthy controls averaged

10.8 +/- 0.8 (SD) uM, a statistically significant difference (p<

0.001).

The sensitivity (detection of positives) and specificity

(non-detection of negatives) of the test in matching CFS patients to

control subjects at NAD(P)H cut-off of 9.5 uM were 0.73 and 0.98.

The researchers also compared NAD(P)H concentrations to other

endocrine and metabolic parameters. A factor analysis, based on the

correlation matrix between all variables, demonstrated that the best

correlations were between the NAD(P)H, serum coenzyme Q10 and urine

pyrroles.

As coenzyme Q10 is the component of a complex series of reactions that

occur within mitochondria, the function of Q10 ultimately is linked to

the generation of energy within the cells. The correlation between

the lower level of coenzyme Q10 and lower NAD(P)H signals for patients

with CFS suggests lower bioenergetics for these subjects.

An inverse correlation was found between the level of serum emission

and the level of pyrroles in urine. The pyrroles are often elevated in

patients with mental illness. This molecule is well known for

bio-toxicity and is associated with emotional stress.

As a result of the study, researchers proposed that fatigue level and

metabolic slowdown in CFS patients can be evaluated and monitored by

serum NAD(P)H concentration measurements.

The measurement of the fluorescence of reduced nicotinamide adenine

dinucleotide in serum provides a non-invasive assay to estimate

metabolism and fatigue levels in CFS patients. Following patient

NAD(P)H levels over time may aid in selecting therapeutic strategies

and monitoring treatment outcome.

To read this and other articles written by Riordan Clinic researchers,

go tohttp://www.riordanclinic.org/research/journal-articles.shtml.

The Riordan Clinic is a progressive nutrition-based medical clinic

located in Wichita, Kansas. For 36 years, the Riordan Clinic has

integrated lifestyle and nutrition to help patients find the

underlying causes of their illness. Since the inception in 1975, the

mission has been clear and unwavering to " .stimulate an epidemic of

health. "

SOURCE Riordan Clinic

Copyright©2010 PR Newswire.

All rights reserved

---------------------------------------------

Send posts toCO-CURE@...

Unsubscribe athttp://www.co-cure.org/unsub.htm

Select list topic options athttp://www.co-cure.org/topics.htm

---------------------------------------------

Co-Cure's purpose is to provide information from across the spectrum of

opinion concerning medical, research and political aspects of ME/CFS and/or

FMS. We take no position on the validity of any specific scientific or

political opinion expressed in Co-Cure posts, and we urge readers to

research the various opinions available before assuming any one

interpretation is definitive. The Co-Cure website<www.co-cure.org> has a

link to our complete archive of posts as well as articles of central

importance to the issues of our community.

---------------------------------------------